COVID-19 Vaccine Distribution

Contents

Executive summary......................................................................................................2
Introduction..................................................................................................................2
System design/develop..............................................................................................3
Challenges in Vaccine Distribution............................................................................5
Production...................................................................................................................5
Prioritization...............................................................................................................5
Distribution.................................................................................................................5
Challenges in Health Outcomes..................................................................................6
Adenoviral Vector Vaccines.......................................................................................6
Duration of Immunity.................................................................................................6
Coordination in Vaccine Distribution........................................................................7
Disease Spread............................................................................................................7
Economic Impact........................................................................................................7
Recommendation..........................................................................................................8
Conclusion.....................................................................................................................8
References.....................................................................................................................9
Appendix:....................................................................................................................10
Availability Assumptions.........................................................................................10
Additional Considerations for Early Vaccination Planning.....................................11

Executive summary
Because multiple candidates for COVID-19 approach human-use clearance,
regulators around the world are establishing rigorous guidelines for vaccine delivery
and control that can fix and ideally prevent issues created by the early marketing. This
early article discusses the problems in four core fields – infrastructure, patient effects,
user-centric impacts and connectivity – in relation to vaccine delivery. The most
important issues that need to be solved include differential delivery, vaccine
effectiveness, immunity length, multi-dose adherence, and privacy record keeping.
While many of these issues were recognized historically and prepared for, others have
not been adequately resolved to meet the needs of different demographic groups with
substantial health inequalities. A comprehensive preparation and attention is required
to include logistics of a global equitable and widespread delivery of vaccine between
different communities and countries of different economic and ethnic backgrounds. In
specialized groups, including infants, older people and immune supported persons, we
also identify particular difficulties with respect to vaccine effectiveness.

Introduction
Over an unprecedented era of accelerated vaccine discovery, growth and
manufacturing, the severity of COVID-19 on national health and economy has started.
The WHO records 48 clinical trials of vaccines and 164 preclinical tested candidates
on November 17, 2020. We expect multilevel difficulties for delivery, access, clinical
data, and compliance with patient criteria, privacy issues, and coordination if any of
these vaccine candidates have been accepted for wide-ranging use. In this article, we
divide this challenge landscape into four different categories: (1) logistics, (2) health
effects, (3) user centric problems, and (4) development. We look at the implications of
these difficulties and focus on the effect on the transmission of disease and on the
economy. In the present, a seamless vaccine system and pipeline for the vaccine
allocation, delivery and administration in all countries worldwide and early advocates
of vaccine has been badly developed. We are looking at the consequences of these
challenges

System design/develop
The greatest operation for vaccine production in COVID-19 lies in North America,
with 36 (46%) confirmed candidate vaccine developers in China against 14 (18%),
Asia (excluding China) and Australia (14%) and Europe (17%) as well (Fig. 2).
Additional attempts have been reported to create vaccines for China, and CEPI is in
dialogue, to clarify its position, with the Chinese Ministry of Science.
The leading developers of successful vaccine applicants COVID-19 are spread across
19 countries covering more than three-quarters of the world's population. However,
no public information is currently available about the vaccine development operation
in Africa or in Latin America, while in these regions vaccine production capability
and regulative mechanisms exist. The epidemiology of COVID-19 could vary in the
field, with an improved cooperation and participation by the Southern hemisphere in
vaccine R&D activities expected to be needed for successful pandemic control.
Challenges in Vaccine Distribution
Hundred million of COVID-19 vaccines face a wide array of difficulties due to the
difficulty of processing, allocation, delivery, administration and surveillance. This are
most important in a shared strategy, which recognizes the convergence of
standardized, large-scale technological problems and the variation of regimes and
communities. In implementing the vaccines COVID-19 we have identified five main
logistical difficulties.

Production
The demand for vaccines for COVID-19 globally outpaces existing supply chains,
although substantial private sector and government support. In America, the CDC has
demonstrated that the general population cannot access a COVID-19 vaccine until
mid-2021. Some countries do not undergo universal vaccination until 2023. Two
crucial issues must be addressed: the decision on the distribution of the small number
of vaccines that would first be available as well as the need for improved efficient
capacity.

Prioritization
Much of the existing COVID-19 vaccine delivery systems indicate that healthcare
workers are the first to obtain future vaccines. Organizations like the National Health
Academy, the WHO and others have all established recommendations for their own
delivery. There exists a CDC vaccine delivery process but the extent of efficacy of
new vaccinations in different populations and length of immune system is limited
because of uncertainty. Once a given authority, such as a state or region, has adopted
guidance on administering vaccinations, more difficulties will occur when it confirms
individuals' eligibility for vaccination. For instance, it may be difficult for an
occupational or entity with pre-existing conditions to validate an eligibility person
without overloading privacy issues or having unnecessary logistic burdens whether
they are assigned for early vaccination. Current US medical record systems are
uniform, which makes it impossible to validate the diagnosis of a person.

Distribution
Any COVID-19 vaccines are anticipated to be stored and delivered safely in the
pipeline. The 'Cold Chain' refers to the need for the storage at low-zero temperatures
of many COVID-19 vaccines currently undergoing clinical trials (including those
developed by Pfizer and BioNTech). In all these procedures, dry ice is also required,
and there is a concern that during delivery of such vaccinations the United States will
suffer from dry ice scarcity. Glass vials of prescription consistency that can survive
sub-zero temperatures may also suffer from shortages in this setting. In several
nations, vaccine-trained refrigerators are lacking in storage centers, which potentially
have a substantial effect on the effectiveness and existence of vaccines. In addition,
there is no adequate data management system in place to monitor and determine the
conditions of transport and storage of vaccines spread broadly in many countries. The
shipping of vaccines during the transit, particularly during international transit, may
be difficult to ensure.

Challenges in Health Outcomes

As COVID-19 vaccines have never seen before, many of the most successful vaccine
candidates have a scarcity of valid clinical evidence on their long-term effectiveness
and side effects. Yet recent research evidence on existing vaccines in progress will
provide an insight into some of the difficulties of deploying these vaccines, as well as
previous awareness of alternative vaccine systems. A new platform of vaccines was
used as a result of the COVID-19 pandemic. The quick production of viable vaccine
candidates was observed with these technologies, but the absence of previous
widespread use of these platforms requires a degree of vigilance and analysis as they
are commonly deployed.

Adenoviral Vector Vaccines

Adenoviral vector vaccines have the primary problem of possible previous host
immunity to the virus vector, which may decrease the potency of the initial
vaccinations or improve them. Moreover, host immunity to adenoviral vectors is
universal in the past, as some reports indicate that many adenovirus subtypes have a
greater serological immunization prevalence than those in Europe and the United
States in sub-Saharan Africa. If the experiments do not properly resolve this, an
adenovirus vaccine in these populations could be significantly less successful.

Duration of Immunity
The amount of time that new vaccines COVID-19 can offer immunity is not known at
this time. Although the short-term safety and effectiveness of vaccine applicants have
so far been shown by clinical trials, it is uncertain how long a vaccine will yield
immunity from COVID-19. Estimates based on immune responses to other related
coronaviruses and on long-term serological responses to normal COVID- 19
infections are currently best predicted. Both of these findings show that COVID-19
immunity cannot survive for longer than 12 months and is likely for vaccinated
people to be much shorter. If the duration of immunity is not well known before the
widespread delivery of the vaccine, appropriate resources to track new COVID-19
infections among individuals with vaccination would be needed.

Coordination in Vaccine Distribution

A comprehensive delivery of a vaccine would entail diverse degrees of cooperation
between various levels of government, private businesses and nonprofit organizations,
both in developed and in developing countries. Cooperation between national health
authorities and state, district and county levels within the developing countries would
be important to determine vaccine requirements and schedule vaccine delivery
accordingly. Developing countries will also need cooperation in the provision and
delivery of vaccines with NGOs or organizations such as the WHO, GAVI, etc.

Disease Spread
The decreased effectiveness of COVID-19 vaccines due to decreasing immunity over
time, logistical storage and transport errors, or differences in results in different
population groups, would result in increased disease transmission due to reduced
immunity prevalence. If no rapid detection of the consequences and cause of
decreased vaccine effectiveness, preventive disease transmission will continue to
escalate until errors in the supply chain and recommendations on vaccination have
been remedied. The preventable extension of COVID-19 could be detected if the
public were not sufficiently advised about the need for double-dose vaccination and
the ongoing compliance with social distancing and masking strategy even after
vaccination.

Economic Impact
It is clear that the already drastic economic effects of COVID-19 are compounded by
a growing volume of preventable COVID-19 infection. Failure to allocate and deliver
vaccinations would also be related to the risks involved with fixing these.
Additionally, states have developed responsibility protection schemes that promote
the production of vaccines, and make governments liable for reparations if
vaccinations are reported as having harmful health effects.

Recommendation
Different private and public sectors, such as states, manufacturers and transport
authorities, have to be coordinated on deliveries of vaccines. A robust, uniform digital
system should be used for continuous recording and reporting of vaccine shipments in
both the space and the delivery pipelines at present. These challenges can be
addressed by basic inventions, such as the bar code of individual vaccines. In addition
to evaluating the effectiveness of the various vaccines and collecting information on
the vaccination rates and compliance of second-dose doses, a privacy approach and
patient follow-up needs to be developed. This record-keeping method is also
important if vaccinations in a variety of populations are to have long-term efficacy
and side effects.
Tools for tracking individuals' vaccines and health results must be customized and
accessible in real time from confident outlets such as the State. These resources must
also encourage users to take part in major observational studies and facilitate passive
user interaction to create reminders, schedules etc. without unwanted user feedback.
Finally, these methods have to be straightforward enough that a person can
comprehend how his data is used. Digital technologies can be more efficient and safe
in both of these ways than the user participation and follow-up using conventional
analogue approaches.
It is also crucial to remember that poorer nations are more severely impacted by many
of the problems in the delivery and administration of vaccines, which illustrate the
importance of the above-mentioned digital solutions.
 Conclusion
In this early draught, we addressed problems related to vaccine production and
delivery of COVID-19, infrastructure, health effects, user-centric and connectivity
concerns. These problems are directly linked to their impacts on the dissemination of
pathogens, personal actions, social influence, economic impact and data protection.
Our study seeks to build a roadmap of observations on the unparalleled landscape of
widespread vaccine delivery for states, institutions, and individuals.
Any of these challenges remain unaffected by existing vaccine programs and
recommendations. For these purposes, it is critical to establish mechanisms and
methods for the governments, organizations, researchers, and individuals to resolve
these challenges in the months and years ahead.
In future work, strategies and how current system can be strengthened to address these
problems can be best defined. We hope that we will also address some challenges
mentioned in this article and suggest digital alternatives for privacy.
Advances in technology and global collaboration have contributed to the accelerated
production of COVID-19 vaccine candidates, which are apparently extremely
successful. In order to guarantee the equal and efficient delivery of these lifesaving
vaccinations to everyone, the same powers must now be used in a consistent and
privacy-oriented way.

References
1. AAMC, (2020) we can’t defeat covid-19 without vaccinating children. There aren’t
even any kids’ clinical trials yet.
2. Accenture. Accenture vaccine management solution, 2020.
3. AstraZeneca, (2020) Covid-19 vaccine azd1222 clinical trials resumed in the UK.
4. The World Bank. Country engagement.
5. BBC, (2020) Coronavirus: Bill gates ‘microchip’ conspiracy theory and other vaccine
claims fact-checked.
6. BBC Stella Immanuel, (2020) the doctor behind unproven coronavirus cure claim.
7. James Bell, (2020) David Butler, Chris Hicks, and Jon Crowcroft. Trace secure:
Towards privacy preserving contact tracing.
8. Alex Berke, (2020) Michiel Bakker, Praneeth Vepakomma, Kent Larson, and Alex
’Sandy’ Pentland. Assessing disease exposure risk with location data: A proposal for
cryptographic preservation of privacy.
9. Joe Biden, (2020) Joe and kamala’s plan to beat covid-19.
10. Joe Biden, (2020) the biden plan to combat coronavirus (covid-19) and prepare for
future global health threats.
11. Becky Brown, (2020) Dominic Kelly, Dominic Wilkinson, and Julian Savulescu. The
scientific and ethical feasibility of immunity passports. The Lancet Infectious
Diseases.
12. Susan P Buchbinder, (2020) M Juliana McElrath, Carl Dieffenbach, and Lawrence
Corey. Use of adenovirus type-5 vectored vaccines: a cautionary tale. The Lancet.

Appendix: COVID-19 Vaccination Scenarios for Jurisdictional Planning—Phase 1,

Q4 2020 (updated 12/18/2020)
Scenario 1: FDA has authorized vaccine A for Emergency Use Authorization (EUA)
in 2020

Availability Assumptions
Additional Considerations for Early Vaccination Planning